Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sinovac Biotech Ltd (SVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 642.44M USD | Price to earnings Ratio 6.66 | 1Y Target Price 3.52 |
Price to earnings Ratio 6.66 | 1Y Target Price 3.52 | ||
Volume (30-day avg) - | Beta 0.06 | 52 Weeks Range 6.47 - 6.47 | Updated Date 06/29/2025 |
52 Weeks Range 6.47 - 6.47 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 850.08% | Basic EPS (TTM) 0.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.61% | Operating Margin (TTM) 42.26% |
Management Effectiveness
Return on Assets (TTM) 11.46% | Return on Equity (TTM) 25.16% |
Valuation
Trailing PE 6.66 | Forward PE - | Enterprise Value 297087285 | Price to Sales(TTM) 1.83 |
Enterprise Value 297087285 | Price to Sales(TTM) 1.83 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 0.04 | Shares Outstanding 99294704 | Shares Floating 59508332 |
Shares Outstanding 99294704 | Shares Floating 59508332 | ||
Percent Insiders 51.42 | Percent Institutions 32.02 |
Upturn AI SWOT
Sinovac Biotech Ltd
Company Overview
History and Background
Sinovac Biotech Ltd. was founded in 2001. It's a biopharmaceutical company focused on researching, developing, manufacturing, and commercializing vaccines for human use, protecting against infectious diseases.
Core Business Areas
- Vaccine Development and Production: Focuses on developing and producing vaccines for various infectious diseases, including COVID-19, influenza, hepatitis A & B, EV71, and mumps. It's a major part of the company's revenue source.
Leadership and Structure
Details regarding the leadership team and organizational structure are not readily available in public US stock information due to its private nature after delisting.
Top Products and Market Share
Key Offerings
- CoronaVac (COVID-19 Vaccine): An inactivated COVID-19 vaccine. Competitors include Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ). Market share is difficult to determine accurately due to varied global distribution, particularly because the company is private.
Market Dynamics
Industry Overview
The vaccine market is driven by global health concerns, technological advancements, and government initiatives. Demand is affected by disease outbreaks, aging populations, and vaccine hesitancy.
Positioning
Formerly, Sinovac was a significant player, especially in developing countries. Now, it is privately owned.
Total Addressable Market (TAM)
The global vaccine market is estimated to reach hundreds of billions of dollars. Sinovac's TAM access is now influenced by its private status.
Upturn SWOT Analysis
Strengths
- Proven vaccine development capabilities
- Established manufacturing infrastructure
- Experience in emerging markets
Weaknesses
- Reliance on a few key products
- Geographic concentration of sales (Historically)
- Limited presence in developed markets (Historically)
Opportunities
- Expanding into new vaccine markets
- Developing new vaccine technologies
- Partnerships with international organizations
Threats
- Intense competition from established players
- Regulatory hurdles
- Vaccine hesitancy
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- JNJ
- GSK
Competitive Landscape
Sinovac faces competition from established players with strong R&D capabilities, distribution networks, and regulatory expertise. Sinovac's competitive advantage previously lied in affordability and accessibility.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth was driven by vaccine sales, particularly CoronaVac. Now, the focus is internal.
Future Projections: Future growth is difficult to project due to its private status.
Recent Initiatives: Information on recent initiatives is not publicly available.
Summary
Sinovac Biotech Ltd, now a private company, faces challenges in the global vaccine market, which is dominated by established players. Its historical reliance on CoronaVac and its previous geographic concentration present strategic hurdles. Success hinges on innovative vaccine development, strategic partnerships, and effective market expansion. Key threats include intense competition, regulatory obstacles, and the continuous evolution of vaccine technologies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available information prior to privatization
- Industry reports
- News articles
Disclaimers:
Data accuracy is limited due to Sinovac Biotech Ltd's current private status. Market share figures are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sinovac Biotech Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2003-11-03 | Chairman, CEO, Pres, MD, GM & Sec. Dr. Weidong Yin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1959 | Website http://www.sinovacbio.com |
Full time employees 1959 | Website http://www.sinovacbio.com | ||
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.